Chudecka-Głaz Anita, Cymbaluk-Płoska Aneta, Menkiszak Janusz, Sompolska-Rzechuła Agnieszka, Byra Elżbieta, Rzepka-Górska Izabella
Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Al, Powstańców Wielkopolskich 72, Szczecin PL-70-111, Poland.
J Ovarian Res. 2014 Feb 14;7:22. doi: 10.1186/1757-2215-7-22.
The aim of our study was to evaluate the behaviour of the human epididymis protein 4 (HE4) in the peritoneal fluid encountered in various female genital diseases.
We enrolled 139 patients, 40 with ovarian cancer (group I), 82 with benign diseases (group II), and 17 with other malignant neoplasms (group III). The HE4 tumor marker concentrations were determined in serum, in the peritoneal effusion and ovarian cyst/ tumor fluids, CA125 in the serum only. We compared the groups, examined correlations and determined corresponding ROC curves. We evaluated the relationship between the HE4 marker concentration in the peritoneal effusion in the group I, depending on the selected prognostic parameters.
The HE4 median value between the study groups did not differ statistically significantly and were as follows: in group I 3322 pmol/L, in the group II 2150 pmol/L and in the group III 627 pmol/L (p = 0.206376 for the groups I and II, p = 0.05929 for the groups I and III and p = 0.0797 for the groups II and III. In group I there were no differences found in the HE4 concentrations in the peritoneal fluid, depending on the stage, grade, the presence of neoplastic cells and the peritoneal dissemination.
The HE4 marker concentrations in the peritoneal fluid are highly irrespective of the pathology observed in the female sexual organ. Therefore, it seems that its determinations in the peritoneal fluid are completely useless in terms of diagnostics. More research is needed on the role of the HE4 marker, especially the place of its formation and possible use in the targeted therapy.
我们研究的目的是评估人附睾蛋白4（HE4）在各种女性生殖系统疾病患者腹腔积液中的表现。
我们招募了139名患者，其中40名患有卵巢癌（I组），82名患有良性疾病（II组），17名患有其他恶性肿瘤（III组）。测定血清、腹腔积液和卵巢囊肿/肿瘤液中的HE4肿瘤标志物浓度，仅测定血清中的CA125。我们比较了各组，检查相关性并确定相应的ROC曲线。我们根据选定的预后参数评估I组腹腔积液中HE4标志物浓度之间的关系。
研究组之间HE4的中位数无统计学显著差异，具体如下：I组为3322 pmol/L，II组为2150 pmol/L，III组为627 pmol/L（I组和II组p = 0.206376，I组和III组p = 0.05929，II组和III组p = 0.0797）。在I组中，根据分期、分级、肿瘤细胞的存在和腹膜播散情况，腹腔积液中的HE4浓度没有差异。
腹腔积液中HE4标志物的浓度与女性生殖器官所观察到的病理情况高度无关。因此，就诊断而言，似乎在腹腔积液中测定HE4完全没有用处。需要对HE4标志物的作用进行更多研究，特别是其形成部位以及在靶向治疗中的可能用途。
